SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950123-00-005090
Filing Date
2000-05-15
Accepted
2000-05-15 00:00:00
Documents
3
Period of Report
1999-12-31

Document Format Files

Seq Description Document Type Size
1 NYMOX PHARMACEUTICAL CORPORATION 20-F 209933
2 RESEARCH AND LICENSE AGREEMENT EX-10.10 82077
3 FINANCIAL DATA SCHEDULE EX-27.0 2325
  Complete submission text file 0000950123-00-005090.txt   296018
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT, QUEBEC CANADA, H4M 2V2 A8
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT, QUEBEC CANADA H4M 2V2 A8 514-332-3222
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 633944
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1